TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15978305

Group type: EXPERIMENTAL
Intervention: Pheniramine maleate 0.3%/naphazoline hydrochloride 0.025% ophthalmic solution
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Olopatadine hydrochloride 0.1% ophthalmic solution
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study: 12416598

Group type: EXPERIMENTAL
Intervention: 2 mg/day of risperidone
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: 4 mg/day of risperidone
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (20 healthy subjects)
Number of subjects: 49
Study: 10599225

Group type: EXPERIMENTAL
Intervention: Sandostatin (200-600 micrograms/day subcutaneously)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional drugs used in acute destructive pancreatitis
Number of subjects: 30
Study: 8773866

Group type: EXPERIMENTAL
Intervention: Acceleromyography (AMG)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Electromyography (EMG)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Visual assessment
Number of subjects: 22
Study: 1481179

Group type: EXPERIMENTAL
Intervention: Inhaled frusemide (40 mg) with placebo pretreatment
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Inhaled frusemide (40 mg) with indomethacin pretreatment
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo inhalation with placebo pretreatment
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo inhalation with indomethacin pretreatment
Number of subjects: 10
Study: 6361565

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Sulindac
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control (19 healthy women)
Number of subjects: 59
Study: 31492788

Group type: EXPERIMENTAL
Intervention: Multi-strategy behavioural intervention integrated into the existing online canteen system, utilizing choice architecture strategies such as menu labelling, placement, prompting, and provision of feedback and incentives.
Number of subjects: 26

Group type: COMPARATOR
Intervention: Standard online canteen ordering system (control group).
Number of subjects: 26
Study: 29498342

Group type: EXPERIMENTAL
Intervention: Synbiotic supplement
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 24686745

Group type: EXPERIMENTAL
Intervention: Low Back Activity Confidence Scale (LoBACS)
Number of subjects: 112
Study: 24982459

Group type: EXPERIMENTAL
Intervention: BM allografts with > median number of plasmacytoid dendritic cells (pDCs)
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: BM allografts with > median number of naïve CD8(+) T cells (CD8Tns)
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: BM allografts with > median number of naïve CD4(+) T cells (CD4Tns)
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: BM allografts with more T cells
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: BM allografts with more pDCs
Number of subjects: 308

Group type: COMPARATOR
Intervention: PB grafts
Number of subjects: 308
Study: 23129084

Group type: EXPERIMENTAL
Intervention: Home-based preventive care program (9 home visits over the first year)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 120
Study: 19781700

Group type: EXPERIMENTAL
Intervention: Misoprostol 200 microg vaginally every 4 hours for up to 72 hours
Number of subjects: 50
Study: 18622139

Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (MFNS) 200 mcg once daily
Number of subjects: 353

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (MFNS)
Number of subjects: 353
Study: 15767334

Group type: EXPERIMENTAL
Intervention: Calcium carbonate (3 g daily, providing 1,200 mg of calcium)
Number of subjects: 672

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 672
Study: 11831781

Group type: EXPERIMENTAL
Intervention: Functional stimulus classes established using a task with nonsense words and symbols, assessed with transfer-of-function test and follow-up test.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stimulus equivalence classes established with computerized matching-to-sample procedures, assessed with postreversal equivalence test and follow-up test.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Follow-up performances after reversals.
Number of subjects: 0
Study: 10524689

Group type: EXPERIMENTAL
Intervention: anti-TNFα monoclonal antibody treatment
Number of subjects: 0
Study: 7733079

Group type: EXPERIMENTAL
Intervention: Pentasa (1 g/day)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Cortenema (100 mg/day)
Number of subjects: 52
Study: 1345695

Group type: EXPERIMENTAL
Intervention: Preoperative artificial feeding (enteral or parenteral) for 7 to 15 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postoperative artificial feeding
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enteral feeding
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New substrates (structured lipids, glutamine, trace elements)
Number of subjects: 0
Study: 6651352

Group type: EXPERIMENTAL
Intervention: 0.18 ppm ozone exposure
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 0.25 ppm ozone exposure
Number of subjects: 28

Group type: COMPARATOR
Intervention: 0.0 ppm ozone exposure (control)
Number of subjects: 28
Study: 31781836

Group type: EXPERIMENTAL
Intervention: Intermittent ScvO2 monitoring
Number of subjects: 152

Group type: COMPARATOR
Intervention: Continuous ScvO2 monitoring
Number of subjects: 152
Study: 30551689

Group type: EXPERIMENTAL
Intervention: Peer-comparison feedback intervention group
Number of subjects: 1421

Group type: COMPARATOR
Intervention: Control group (no feedback via SMS)
Number of subjects: 1421
Study: 29231363

Group type: EXPERIMENTAL
Intervention: Twirling reducing method group (acupuncture at specific acupoints with strong low-frequency twirling reducing method applied at Xiaxi and Taichong)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Needle retaining group (identical acupoints and needle insertion manipulation without reducing method)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Physical therapy group (laser and ultrashort wave treatment)
Number of subjects: 101
Study: 25064594

Group type: EXPERIMENTAL
Intervention: Regular paracetamol (3990 mg/day, three times per day)
Number of subjects: 1652

Group type: EXPERIMENTAL
Intervention: As-needed paracetamol (maximum 4000 mg/day)
Number of subjects: 1652

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1652

Group type: COMPARATOR
Intervention: Regular paracetamol vs placebo
Number of subjects: 1652

Group type: COMPARATOR
Intervention: As-needed paracetamol vs placebo
Number of subjects: 1652

Group type: EXPERIMENTAL
Intervention: Regular paracetamol vs as-needed
Number of subjects: 1652

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 1652
Study: 22056282

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate
Number of subjects: 1507

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1507

Group type: EXPERIMENTAL
Intervention: Maternal general anesthesia
Number of subjects: 1507

Group type: EXPERIMENTAL
Intervention: Gestational age at birth increase (1-week increase)
Number of subjects: 1507
Study: 18199496

Group type: EXPERIMENTAL
Intervention: Early invasive strategy
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Selectively invasive strategy
Number of subjects: 1200
Study: 17848615

Group type: EXPERIMENTAL
Intervention: Invasive treatment strategy
Number of subjects: 2079

Group type: COMPARATOR
Intervention: Conservative treatment strategy
Number of subjects: 2079
Study: 15752407

Group type: EXPERIMENTAL
Intervention: Ranitidine, 50 mg every 8 hours
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 12161404

Group type: EXPERIMENTAL
Intervention: Fluconazole 150 mg once weekly
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Fluconazole 200 mg/day for 7 days followed by fluconazole 150 mg once weekly
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study: 10534635

Group type: EXPERIMENTAL
Intervention: PUVA treatment
Number of subjects: 100

Group type: COMPARATOR
Intervention: Narrow-band (TL-01) phototherapy
Number of subjects: 100
Study: 7819037

Group type: EXPERIMENTAL
Intervention: Calcium carbonate (3,000 mg)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study: 2080484

Group type: EXPERIMENTAL
Intervention: Prazepam drops
Number of subjects: 154

Group type: COMPARATOR
Intervention: 10 mg prazepam tablets
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 154
Study: 7378213

Group type: EXPERIMENTAL
Intervention: Metoprolol (200 mg daily)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Propranolol (160 mg daily)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 30741193

Group type: EXPERIMENTAL
Intervention: Student-Generated Questions (SGQs)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Faculty-Generated Questions (FGQs)
Number of subjects: 10
Study: 28258251

Group type: EXPERIMENTAL
Intervention: Chlamyweb Intervention (self-sampling kits offered)
Number of subjects: 7215
Study: 26091386

Group type: EXPERIMENTAL
Intervention: 5% dapsone gel
Number of subjects: 56

Group type: COMPARATOR
Intervention: 0.75% metronidazole gel
Number of subjects: 56
Study: 24999283

Group type: EXPERIMENTAL
Intervention: Problematic drug use identification
Number of subjects: 3240

Group type: EXPERIMENTAL
Intervention: Correlates of problematic drug use
Number of subjects: 3240

Group type: EXPERIMENTAL
Intervention: Correlates among primary cannabis users
Number of subjects: 3240
Study: 22831548

Group type: EXPERIMENTAL
Intervention: Community-based healthy lifestyle promotion campaign
Number of subjects: 4650

Group type: COMPARATOR
Intervention: Conventional healthcare services (control)
Number of subjects: 4650
Study: 19917377

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg/d
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control (no losartan)
Number of subjects: 66
Study: 17208103

Group type: EXPERIMENTAL
Intervention: Microabrasion using 18% hydrochloric acid and pumice technique
Number of subjects: 8
Study: 15168099

Group type: EXPERIMENTAL
Intervention: Desloratadine 5 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Diphenhydramine 50 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 16894712

Group type: EXPERIMENTAL
Intervention: Zinc oxide-eugenol
Number of subjects: 30

Group type: COMPARATOR
Intervention: 15.5% ferric sulphate
Number of subjects: 30
Study: 9640060

Group type: EXPERIMENTAL
Intervention: General Motor Activity evaluation during rehabilitation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mathew and Barthel scales
Number of subjects: 0
Study: 7865641

Group type: EXPERIMENTAL
Intervention: Amoxycillin 500 mg q.d.s. before meals
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Amoxycillin 500 mg q.d.s. after meals
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Amoxycillin 500 mg q.d.s. before meals (good compliers)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Amoxycillin 500 mg q.d.s. after meals (good compliers)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Good compliance
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Poor compliance
Number of subjects: 80
Study: 1106446

Group type: EXPERIMENTAL
Intervention: Temazepam (15, 20, or 30 mg in hard gelatin capsules or 20 mg in soft gelatin capsules)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Nitrazepam (5 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Amylobarbitone sodium (100 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 31439049

Group type: EXPERIMENTAL
Intervention: DiaLife education program for relatives of diabetes patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 0
Study: 28790412

Group type: EXPERIMENTAL
Intervention: Directed degeneration method for investigating ligand recognition mechanisms of endothelin receptor type A (ETA) with endothelin-1 (ET-1)
Number of subjects: 0
Study: 25565349

Group type: EXPERIMENTAL
Intervention: Self-activating group (participants asked to think about their past throwing experience between trial blocks)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control group (participants maintained their performance across blocks)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Self-activating group (participants practicing a wiffleball hitting task)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control group (participants practicing a wiffleball hitting task)
Number of subjects: 2
Study: 24053433

Group type: EXPERIMENTAL
Intervention: Colloid fluid loading for 90 min, guided by changes in pulmonary artery occlusion pressure (PAOP) or central venous pressure (CVP)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Colloid fluid loading for 90 min, guided by changes in PAOP or CVP
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Changes in SvO2
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Changes in GEDVI
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: SvO2 increases
Number of subjects: 37
Study: 22165032

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine during anesthesia and for 6 days after recovery from anesthesia
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group treated with oral lefoxidine 0.2 mg three times daily after recovery from anesthesia
Number of subjects: 60
Study: 19368937

Group type: EXPERIMENTAL
Intervention: Hypocaloric diet with Optisource (1109.3 kcal/day, 166.4g carbohydrates, 63g proteins, 21.3g lipids)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Nutritional counseling with a decrease of 500 cal/day
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Hypocaloric diet with Optisource
Number of subjects: 36

Group type: COMPARATOR
Intervention: Nutritional counseling
Number of subjects: 36
Study: 16525139

Group type: EXPERIMENTAL
Intervention: Thalidomide
Number of subjects: 668

Group type: COMPARATOR
Intervention: Control (no thalidomide)
Number of subjects: 668
Study: 12393732

Group type: EXPERIMENTAL
Intervention: PCV7 vaccine administered before transplantation and at 3 months, 6 months, and 12 months post-transplantation
Number of subjects: 96

Group type: COMPARATOR
Intervention: No vaccine administered before transplantation
Number of subjects: 96
Study: 11246617

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine (15 mg/day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 9065635

Group type: EXPERIMENTAL
Intervention: Oral emedastine difumarate
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Azelastine hydrochloride
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Xiao qing long tang (homeopathic decongestant)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Intranasal fluticasone propionate aqueous nasal spray
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (pre-treatment measurements)
Number of subjects: 45
Study: 8349380

Group type: EXPERIMENTAL
Intervention: Dynamic vectorcardiography
Number of subjects: 74

Group type: COMPARATOR
Intervention: QRS scoring of the conventional 12-lead electrocardiogram
Number of subjects: 74
Study: 2949309

Group type: EXPERIMENTAL
Intervention: Intravenous ketoprofen (100 mg in 5 ml)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (5 ml)
Number of subjects: 10
Study: 29497812

Group type: EXPERIMENTAL
Intervention: 2-L polyethylene glycol with ascorbic acid (PEG/Asc)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Sodium picosulfate with magnesium citrate (SP/MC)
Number of subjects: 223
Study: 27391495

Group type: EXPERIMENTAL
Intervention: Mini-plate-anchored face-mask therapy (n = 5)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Intermaxillary elastics to miniplates (n = 6)
Number of subjects: 11
Study: 24191968

Group type: EXPERIMENTAL
Intervention: Simulated head injury
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Poor effort on performance validity tests (PVTs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (valid performance on PVTs)
Number of subjects: 0
Study: 22294268

Group type: EXPERIMENTAL
Intervention: Virtual temporal bone dissection system
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard cadaveric temporal bones
Number of subjects: 80
Study: 20858150

Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 18446020

Group type: EXPERIMENTAL
Intervention: Vit/Min plus 4.5 g FOS plus 200 mg fish oil-derived DHA (DHA-FOS group)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Basic vitamin-mineral supplement (Vit/Min group)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Vit/Min plus 4.5 g fructo-oligosaccharide (FOS group)
Number of subjects: 144
Study: 16339289

Group type: EXPERIMENTAL
Intervention: Once-monthly ibandronate (150 mg)
Number of subjects: 1609

Group type: EXPERIMENTAL
Intervention: Once-monthly ibandronate (100 mg)
Number of subjects: 1609

Group type: EXPERIMENTAL
Intervention: Once-monthly ibandronate (50 mg)
Number of subjects: 1609

Group type: COMPARATOR
Intervention: Daily ibandronate
Number of subjects: 1609

Group type: EXPERIMENTAL
Intervention: All treatment arms
Number of subjects: 1609
Study: 15655620

Group type: EXPERIMENTAL
Intervention: FOBT screening
Number of subjects: 8963

Group type: EXPERIMENTAL
Intervention: Colonoscopy after positive FOBT
Number of subjects: 8963

Group type: COMPARATOR
Intervention: Control group (non-FOBT participants)
Number of subjects: 8963
Study: 10659695

Group type: EXPERIMENTAL
Intervention: Automated telephone disease management (ATDM) calls with telephone nurse follow-up
Number of subjects: 248

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 248
Study: 9147428

Group type: EXPERIMENTAL
Intervention: Cognitive/behavioral skills‐building intervention (n = 199)
Number of subjects: 399

Group type: COMPARATOR
Intervention: Control group (brief standardized counseling session, n = 200)
Number of subjects: 399
Study: 8401546

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy for 8 weeks
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Brief psychoeducational interventions
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Intensive psychological, pharmacologic, and experimental treatment approaches
Number of subjects: 39
Study: 2946608

Group type: EXPERIMENTAL
Intervention: Laparoscopic electrocautery
Number of subjects: 90

Group type: COMPARATOR
Intervention: Danazol therapy
Number of subjects: 90
Study: 31420960

Group type: EXPERIMENTAL
Intervention: CET group (group aftercare)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: CET app (fully automated mobile phone app aftercare)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Aftercare as usual
Number of subjects: 164
Study: 29017905

Group type: EXPERIMENTAL
Intervention: Combined sensory play (fruit and non-food)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Non-food sensory play
Number of subjects: 100

Group type: COMPARATOR
Intervention: Fruit taste exposure
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control play
Number of subjects: 100
Study: 27012407

Group type: EXPERIMENTAL
Intervention: Drug-Eluting Stents (DES)
Number of subjects: 36117

Group type: COMPARATOR
Intervention: Bare-Metal Stents (BMS)
Number of subjects: 36117
Study: 23228587

Group type: EXPERIMENTAL
Intervention: Attention Training
Number of subjects: 45

Group type: COMPARATOR
Intervention: Cognitive Therapy
Number of subjects: 45
Study: 22905702

Group type: EXPERIMENTAL
Intervention: 5% permethrin cream
Number of subjects: 220

Group type: COMPARATOR
Intervention: 1% lindane lotion
Number of subjects: 220
Study: 21253453

Group type: EXPERIMENTAL
Intervention: FFNS 110 mcg once daily
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 16835006

Group type: EXPERIMENTAL
Intervention: hCG (200 IU/day)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: hMG (225 IU/day)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: rFSH (200 IU/day)
Number of subjects: 51
Study: 15134971

Group type: EXPERIMENTAL
Intervention: Contact Laser Prostatectomy (CLP)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Transurethral Resection of the Prostate (TURP)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Electrovaporization
Number of subjects: 141
Study: 12067143

Group type: EXPERIMENTAL
Intervention: Disopyramide (DP)
Number of subjects: 33
Study: 9520929

Group type: EXPERIMENTAL
Intervention: brief behavioral intervention
Number of subjects: 36

Group type: COMPARATOR
Intervention: wait list control
Number of subjects: 36
Study: 7854360

Group type: EXPERIMENTAL
Intervention: Whitfield's cream (3% salicylic acid and 6% benzoylic acid)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Clotrimazole cream
Number of subjects: 138
Study: 2913103

Group type: EXPERIMENTAL
Intervention: Protocol for smoking management and lecture on smoking consequences; nicotine gum freely available to patients; stickers attached to charts; gum and reminders.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Nicotine gum availability
Number of subjects: 50
Study: 4330318

Group type: EXPERIMENTAL
Intervention: Lysostaphin nasal spray
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neosporin ointment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 0
Study: 30940887

Group type: EXPERIMENTAL
Intervention: Oral prednisolone (1 mg/kg daily for 3–7 days)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Periocular injection of methylprednisolone (40 mg, 1–3 days before vitrectomy)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Oral prednisolone in CD subsided eyes
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Oral prednisolone in CD persistent eyes
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Periocular injection in CD subsided eyes
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Periocular injection in CD persistent eyes
Number of subjects: 75

Group type: COMPARATOR
Intervention: CD subsided eyes
Number of subjects: 75

Group type: COMPARATOR
Intervention: CD persistent eyes
Number of subjects: 75
Study: 28662509

Group type: EXPERIMENTAL
Intervention: C1‐INH 500 U
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: C1‐INH 1,000 U
Number of subjects: 6
Study: 26355026

Group type: EXPERIMENTAL
Intervention: High-dose lipo-PGE1
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Low-dose lipo-PGE1
Number of subjects: 60

Group type: COMPARATOR
Intervention: Mecobalamin (MeCbl) alone
Number of subjects: 60